CBLL
CeriBell, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.45
P/S
7.85
EV/EBITDA
-13.49
DCF Value
$-40.01
FCF Yield
-6.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.9%
Operating Margin
-65.6%
Net Margin
-60.0%
ROE
-31.8%
ROA
-27.4%
ROIC
-32.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $24.8M | $-13.5M | $-0.36 |
| FY 2025 | $89.1M | $-53.4M | $-1.46 |
| Q3 2025 | $22.6M | $-13.5M | $-0.37 |
| Q2 2025 | $21.2M | $-13.6M | $-0.38 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.11
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.